Use of Personalized Recommendations, Through Genetic and Lifestyle Data, to Improve Healthcare Staff Wellbeing

Sponsor
FitnessGenes Ltd. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06042452
Collaborator
(none)
500
1
2

Study Details

Study Description

Brief Summary

With the NHS under increasing pressure and strain, the health and wellbeing of staff is an important area to prioritize, to help reduce staff stress levels and increase retention of staff. This study will look to explore how efficacious personalised insights and recommendations are, based on genetic and lifestyle information, at improving the health and wellbeing of NHS employees. It will also explore how sustainable these recommendations are for long-term change. Recruitment of NHS staff as participants will take place across multiple NHS trusts including Bradford Teaching Hospital NHS Trust and Sandwell and West Birmingham NHS Trust.

Following consent to partake in the trial, participants will be asked to complete a pre-trial questionnaire which will explore health and wellbeing interests and motivations, perceptions of genetic testing, and a baseline measure of mental and physical wellbeing using a standardised and validated questionnaire (5-item World Health Organisation Well-being Index (WHO-5)). This, and all further questionnaires, will be completed online.

Participants will undertake a DNA test provided by FitnessGenes, free of charge. This test will require participants to provide a saliva sample via a spit test. This sample will then be analysed at an ISO-accredited laboratory and results provided back to the participant within 2-3 weeks. While awaiting the results, participants will have access to lifestyle traits calculated using questionnaire data collected when creating a FitnessGenes account.

Once their genetic data is added to a participant's FitnessGenes accounts, they will be asked to spend two weeks exploring this information. A questionnaire will then be completed to reassess participant's wellbeing measures and any changes in their perceptions of DNA testing. At this stage, some semi-structured interviews may be conducted, to those who consent to this, to gain further insight.

A 3-month follow up will be completed to assess whether the platform has had any long-lasting impacts on participants' health and wellbeing.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Genetic
N/A

Detailed Description

This will be a 6-week long study to explore the impact of FitnessGenes' platform, with a follow-up after 3 months. NHS staff from multiple NHS trusts will be recruited to partake in the study.

Following consent to partake in the trial, participants will be asked to complete a pre-trial questionnaire which will explore health and wellbeing interests and motivations, alongside taking a baseline measure of mental and physical wellbeing using the 5-item World Health Organization Well-being Index (WHO-5) which has been clinically validated. This, and all further questionnaires, will be completed online.

Participants will undertake a DNA test provided by FitnessGenes, free of charge. This test will require participants to provide a saliva sample via a spit test. This sample will then be analysed at an ISO-accredited laboratory and results provided back to the participant within 2-3 weeks. Test result data is stored in an encrypted format and saliva samples are anonymized using unique barcodes printed on the collection tubes, which do not contain any Personal Information. User identity data (email, name, address, contact info etc.) is kept in a separate database to user personal data (demographic, biometric, lifestyle, genetic etc.). This means all personal data is already kept in an anonymised form.

Once their genetic data is added to a participant's FitnessGenes account, they will be asked to spend a week exploring this upgraded information. A feedback questionnaire will be completed, 3 weeks after they have received their results, to assess participant's experiences of the platform and their results. At this stage, some semi-structured interviews may be conducted, to those who consent to this, to gain further insight.

A 3-month follow up, after the baseline measures were taken, will be completed to assess whether the platform has had any long-lasting impacts on participants' health and wellbeing. This follow up will be completed via a short online questionnaire.

The primary aim of the study is to assess changes in subjects' well-being, as evaluated by the 5-item World Health Organisation Well-being Index (WHO-5).

The investigators will adopt a repeated measures analysis, collecting raw WHO-5 scores from the same subjects at three discrete time points: baseline (i.e. before genetic analysis), 3 weeks after receiving genetic results and at 3 months after baseline. The investigators will also assess the internal consistency of the WHO-5 by performing a Cronbach's alpha test at the three time points.

To assess changes in well-being, raw WHO-5 scores (ranging from 0 to 25) will be multiplied by 4 and transformed into final scores of 0 - 100 for each subject. Descriptive statistics (mean and standard deviation) will be calculated for the 5 individual items of the WHO-5 and the final WHO-5 scores (0-100).

The main dependent variable to be evaluated will be the final WHO-5 Score (ranging from 0-100). The investigators will use repeated measures analysis to assess changes in mean final WHO-5 score across the three different time points.

Briefly, the investigators will assess the distributions of the WHO-5 scores and perform basic tests of normality (including Q-Q plot and performing a Shapiro-Wilkes test) and sphericity/equal variances (Mauchly's test). Depending on the distributions of this data, the investigators will select the appropriate statistical test to assess changes in mean final WHO-5 score.

Assuming normality and sphericity of data and no outliers, the investigators will perform a repeated measures (within-subjects) ANOVA to assess whether the mean final WHO-5 score is statistically significantly different across the three time points. Post-hoc tests will include paired T-tests to make pairwise comparisons in mean final WHO-5 score between the time points, with P-values adjusted using the Bonferroni multiple testing correction method. Depending on the demographic make-up of the subjects, the investigators may include other moderator variables (e.g. gender) to assess for interactions with time point.

If the assumptions behind these parametric tests are violated, a non-parametric alternative (e.g. Friedmans test) will be used to assess changes in mean WHO-5 score. All statistical analysis will be performed using R.

Repeated measures analysis will be used to evaluate the secondary outcomes related to user experience and perceptions of genetic testing.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Exploring the Utility and Effectiveness of Personalised Insights and Recommendations, Using Genetic and Lifestyle Data, to Improve Employee Health and Wellbeing
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Genetic

Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive

Genetic: Genetic
A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.

Outcome Measures

Primary Outcome Measures

  1. Change in physical and psychological well-being [Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at a 3 month follow-up]

    5-Item World Health Organisation Well-being Index (WHO-5). This uses a Likert Scale from 0 ('At no time') to 5 ('All of the time'). A raw score of 0 (lowest well-being) to 25 (highest well-being) is possible on the WHO-5.

Secondary Outcome Measures

  1. Perceptions of DNA testing [Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up]

    A questionnaire using a scale from Strongly against to Strongly for.

  2. How sustainable are the personalized recommendations [Measurements taken at 3 month follow-up]

    A questionnaire that will cover whether recommendations were followed (Yes/No), for how long (1-5 days, 1-2 weeks, 3-4 weeks, 1 month, > 2 months) and how easy participants found implementing the recommendations (scale from Very hard to very easy).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Health care staff within the NHS (including both clinical and administrative)

  • Able to proficiently read English (reports are only produced in English)

Exclusion Criteria:
  • Unable to proficiently read English

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • FitnessGenes Ltd.

Investigators

  • Principal Investigator: Stuart Grice, DPhil, FitnessGenes Ltd.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
FitnessGenes Ltd.
ClinicalTrials.gov Identifier:
NCT06042452
Other Study ID Numbers:
  • FG-NHS-Wellbeing
First Posted:
Sep 18, 2023
Last Update Posted:
Sep 18, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Sep 18, 2023